Developer docs
API playgroundTry for free, no card

Search company profiles

Burning Rock Biotech

Full company profile

uuid00063l6

Namestring
Burning Rock Biotech
Legal namestring
Burning Rock Biotech Limited
Websiteurl
brbiotech.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer genomic testing, companion diagnostics, liquid biopsy assays, multi-cancer early detection, minimal residual disease testing
Industry5 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Central Laboratory Testing Services
TypeSubscription Recurring
Description

NGS-based cancer testing services performed at Burning Rock's central laboratories (Guangzhou and Irvine) for cancer patients, providing therapy selection and molecular profiling results to guide treatment decisions.

brbiotech.com
2In-Hospital Testing Business
TypeOne Time License
Description

Sale of NGS testing kits and support services to hospitals that have established in-house NGS testing platforms. Revenue generated from kit sales, technical support, and ongoing services. Growing revenue share from 43% in Q1 2025 to 49% in Q1 2026, representing RMB52.8 million (US$7.6 million) in Q1 2026.

brbiotech.com
3Pharma Research and Development Services
TypeProfessional Services
Description

Comprehensive biomarker detection and companion diagnostics development services for pharmaceutical companies, including genomic data solutions, clinical trial solutions, precision patient recruitment, and CDx development and commercialization. Revenue was RMB22.8 million in Q1 2026, with 34.5% growth in 2025. The company partners with over 150 pharmaceutical enterprises globally.

brbiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1OncoScreen
Description

NGS-based cancer mutation profiling tissue kits for solid tumor testing

brbiotech.com
+7 more records
Core offering1 text field

Burning Rock Biotech develops and sells NGS-based diagnostic kits (tissue and liquid biopsy panels) and provides central laboratory cancer genomic testing services, multi-cancer early detection blood tests, and MRD monitoring products. It also delivers companion diagnostics development and biomarker services to pharmaceutical companies, supported by CLIA/CAP-accredited labs in China and the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Stage-shifting potential of 38.7%-46.4% of patients through annual OverC testing, improving five-year survival rate for 33.1%-40.4% of patients.
+4 more records
Product overview1 text field

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company offering an integrated portfolio of NGS-based diagnostic products and services. The core product lines include tissue-based testing products (OncoScreen Plus, OncoScreen Focus) and liquid biopsy solutions (OncoCompass Plus, OncoCompass Target), all available as CE-IVDD marked or NMPA-approved kits. The OncoScreen Focus CDx serves as the companion diagnostic variant for targeted therapies. For early cancer detection, the company offers the OverC multi-cancer detection blood test based on ELSA-seq technology, which holds both CE marking and FDA/NMPA Breakthrough Device Designation. Supporting platforms include the MAGNIS BR automated library preparation system and OncoMaster data analysis system. The company also provides comprehensive pharma services including biomarker detection and CDx development through its globally accredited laboratory network. These products and services work together to cover the full precision oncology cycle from early detection and therapy selection to recurrence monitoring, supported by in-house developed technologies including ELSA-seq methylation profiling, HS-UMI ultra-deep sequencing, and tumor-informed MRD detection (CanCatch).

Product and service1 record
1OncoCompass Plus (Liquid Biopsy)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Fudan University Shanghai Cancer Center
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Joint study with team led by Professor Haiquan Chen, Professor Hong Hu, and Professor Yang Zhang from Fudan University Shanghai Cancer Center, published in Journal for ImmunoTherapy of Cancer (IF=10.6). Study validated ctDNA-MRD potential for evaluating perioperative treatment response in squamous cell lung cancer.

brbiotech.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for ctDNA testing services supporting clinical studies on Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. CanCatch provided high-sensitivity ctDNA testing services for NSCLC studies presented at 2026 AACR, including one selected for plenary oral session.

3Riken Genesis
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-24
Description

Partnership with Riken Genesis for commercialization of OncoGuide™ OncoScreen™ Plus CDx System in Japan. The CDx system received Manufacturing and Marketing Approval from Japan's MHLW as companion diagnostic for AstraZeneca's capivasertib (Truqap) in breast cancer. Riken Genesis handles distribution, insurance coverage, and market access in Japan.

brbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-11
Description

Joint development and co-commercialization of companion diagnostics for EGFR exon20ins mutation detection supporting sunvozertinib targeted therapy for NSCLC. This represents the first co-developed NGS-based CDx for lung cancer approved by NMPA following CDx guideline release in China.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Collaboration to increase patient access to precision cancer medicines through companion diagnostics development and commercialization.

6Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-25
Description

Master Service Agreement for oncology companion diagnostics development, focusing on clinical trials for MDM2-p53 antagonist brigimadlin (BI 907828) and CDx product development in China. The partnership aims to provide precise treatment options for patients with MDM2-amplified, TP53 wild-type cancers including biliary tract carcinoma.

brbiotech.com
7Merck KGaA (Germany)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-11-17
Description

Collaboration on liquid biopsy-based CDx development using Burning Rock's OncoCompass Target platform, supporting Merck's oncology drug development programs.

brbiotech.com
8IMPACT Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-03
Description

Global strategic partnership for companion diagnostics development for Senaparib (PARP inhibitor) targeting prostate cancer. Includes CDx submissions to both FDA and NMPA, supported by Burning Rock's CLIA and CAP accredited labs.

brbiotech.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-05-19
Description

Launch of PRESCIENT study, the first blood-based, pan-cancer early-detection study in China using multi-omics approach. Expected to enroll 11,879 participants across 22 cancer types. Led by Professor Jie He and Professor Jie Wang from National Cancer Center.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-04-29
Description

Strategic partnership for CDx assay development for ABSK091 (FGFR inhibitor) to detect FGFR genetic alterations in patients with urothelial carcinoma. Abbisko has exclusive global rights for development, manufacture, and commercialization.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-06-29
Description

Strategic partnership for co-development and commercialization of companion diagnostics for pralsetinib (Blueprint Medicines) for detection of RET alterations in cancer patients in China.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-05-11
Description

Strategic cooperation to promote development and standardization of NGS-based cancer therapy selection in China based on NextSeq 550Dx system. First genetic testing company in China to achieve development of IVD tests for both ctDNA and tissue based on NextSeq 550Dx system.

13Shanghai Zhongshan Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-05-07
Description

Collaboration on PREDICT (Pan-CanceR Early DetectIon ProjecT) study, the first early detection study in multiple cancer types in China. 14,000 patient enrollment expected. Led by Professor Jia Fan, Fellow of Chinese Academy of Sciences and President of Shanghai Zhongshan Hospital.

brbiotech.com
14CTONG (Chinese Thoracic Oncology Group)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-08-01
Description

Co-founded NGS Clinical Research Lab at Guangzhou International Bio Island for non-profit clinical studies. 3,000m2 facility with 19 independent labs covering sample processing, nucleic acid extraction, library construction, sequencing, and data analysis. CTONG's first partner for founding NGS lab.

brbiotech.com
15AstraZeneca China
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Designated as AstraZeneca's sole strategic NGS lung cancer testing partner. Participated in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD). Also launched China's first NGS charitable project for ovarian cancer - 'Love Me, Test Me' BRCA testing project.

brbiotech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US-listed oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE, RaDaR MRD). Comparable in oncology-focused lab services, NGS profiling, and pharma/biopharma clinical trial support.

TypeDirect peer
Description

US-based molecular profiling company offering MI Profile tumor/NGS profiling and Caris Assure liquid biopsy MRD tests. Directly comparable to Burning Rock's tissue and blood-based NGS oncology products targeting therapy selection and recurrence monitoring.

TypeDirect peer
Description

US-listed molecular diagnostics company with Signatera tumor-informed MRD test and oncology NGS products. Direct comparable in liquid biopsy MRD detection (vs. Burning Rock's CanCatch) and oncology therapy selection testing.

TypeBroad incumbent
Description

Roche-owned leader in NGS-based comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head with Burning Rock's OncoScreen Plus and OncoCompass products in CDx and tissue profiling, with broader pharma services scale.

TypeBroad incumbent
Description

US-listed molecular diagnostics company with Cologuard (CRC screening), Oncotype DX, and emerging liquid biopsy products. Comparable in cancer molecular diagnostics for therapy selection and screening, though broader and larger-scale than Burning Rock.

TypeDirect peer
Description

US-listed liquid biopsy and NGS oncology diagnostics company offering ctDNA-based therapy selection and MRD tests (Guardant360, Reveal). Directly comparable to Burning Rock's OncoCompass liquid biopsy franchise in product category, customer base (oncologists/hospitals), and business model.

TypeDirect peer
Description

US-listed NGS-based oncology testing company offering NeXT Personal MRD test and ImmunoID Next tumor profiling. Comparable in tumor-informed liquid biopsy MRD and comprehensive NGS oncology panels for pharma and clinical customers.

8Tempus AI
TypeDirect peer
Description

US-listed precision medicine company offering NGS-based oncology profiling (Tempus xT, xR), AI-enabled clinical decision support, and biopharma data services. Comparable in NGS oncology testing, pharma CDx/biomarker services, and AI/bioinformatics platform offerings.

TypeEmerging player
Description

US/China-based liquid biopsy and NGS diagnostics company offering cell-free DNA/RNA assays and MRD detection for pharma and clinical customers. Comparable in liquid biopsy ctDNA technology, MRD focus, and dual US-China operational footprint.

TypeDirect peer
Description

China-based NGS oncology diagnostics competitor offering Gene+Seq tumor profiling, liquid biopsy, and pharma CDx services. Closest China-domestic direct peer to Burning Rock in NGS oncology testing market, technology, and pharma partnership model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Burning Rock Biotech

Precision Oncology Diagnosticsbrbiotech.com

Burning Rock Biotech firmographics

Firmographics
Name
Burning Rock Biotech
Legal name
Burning Rock Biotech Limited
Website
https://brbiotech.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Burning Rock Biotech industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Cancer genomic testing
  • Companion diagnostics
  • Liquid biopsy assays
  • Multi-cancer early detection
  • Minimal residual disease testing

Where Burning Rock Biotech is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Burning Rock Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Central Laboratory Testing Services: NGS-based cancer testing services performed at Burning Rock's central laboratories (Guangzhou and Irvine) for cancer patients, providing therapy selection and molecular profiling results to guide treatment decisions.
  2. In-Hospital Testing Business: Sale of NGS testing kits and support services to hospitals that have established in-house NGS testing platforms. Revenue generated from kit sales, technical support, and ongoing services. Growing revenue share from 43% in Q1 2025 to 49% in Q1 2026, representing RMB52.8 million (US$7.6 million) in Q1 2026.
  3. Pharma Research and Development Services: Comprehensive biomarker detection and companion diagnostics development services for pharmaceutical companies, including genomic data solutions, clinical trial solutions, precision patient recruitment, and CDx development and commercialization. Revenue was RMB22.8 million in Q1 2026, with 34.5% growth in 2025. The company partners with over 150 pharmaceutical enterprises globally.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Burning Rock Biotech product offering

Product offering

Core offering

Burning Rock Biotech develops and sells NGS-based diagnostic kits (tissue and liquid biopsy panels) and provides central laboratory cancer genomic testing services, multi-cancer early detection blood tests, and MRD monitoring products. It also delivers companion diagnostics development and biomarker services to pharmaceutical companies, supported by CLIA/CAP-accredited labs in China and the US.

Product overview

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company offering an integrated portfolio of NGS-based diagnostic products and services. The core product lines include tissue-based testing products (OncoScreen Plus, OncoScreen Focus) and liquid biopsy solutions (OncoCompass Plus, OncoCompass Target), all available as CE-IVDD marked or NMPA-approved kits. The OncoScreen Focus CDx serves as the companion diagnostic variant for targeted therapies. For early cancer detection, the company offers the OverC multi-cancer detection blood test based on ELSA-seq technology, which holds both CE marking and FDA/NMPA Breakthrough Device Designation. Supporting platforms include the MAGNIS BR automated library preparation system and OncoMaster data analysis system. The company also provides comprehensive pharma services including biomarker detection and CDx development through its globally accredited laboratory network. These products and services work together to cover the full precision oncology cycle from early detection and therapy selection to recurrence monitoring, supported by in-house developed technologies including ELSA-seq methylation profiling, HS-UMI ultra-deep sequencing, and tumor-informed MRD detection (CanCatch).

Differentiator

Problem solved

Functional benefit

Brands

  • OncoScreen: NGS-based cancer mutation profiling tissue kits for solid tumor testing
  • OncoCompass
  • OverC
  • CanCatch
  • OncoMaster
  • ELSA-seq
  • OncoGuide
  • MAGNIS BR

Products and services

  • OncoCompass Plus (Liquid Biopsy)

Quantifiable outcome

  • Stage-shifting potential of 38.7%-46.4% of patients through annual OverC testing, improving five-year survival rate for 33.1%-40.4% of patients.
  • +4 more outcomes

Companies that use Burning Rock Biotech

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Burning Rock Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability8 records

Feature5 records

Burning Rock Biotech partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major and core.

  • Fudan University Shanghai Cancer CentermajorStrategic or Co-development Partner · 9 June 2026Joint study with team led by Professor Haiquan Chen, Professor Hong Hu, and Professor Yang Zhang from Fudan University Shanghai Cancer Center, published in Journal for ImmunoTherapy of Cancer (IF=10.6). Study validated ctDNA-MRD potential for evaluating perioperative treatment response in squamous cell lung cancer.
  • D3 BiomajorStrategic or Co-development Partner · 1 January 2026Partnership for ctDNA testing services supporting clinical studies on Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. CanCatch provided high-sensitivity ctDNA testing services for NSCLC studies presented at 2026 AACR, including one selected for plenary oral session.
  • Riken GenesiscoreChannel Partner/ Reseller/ Distributor · 24 September 2025Partnership with Riken Genesis for commercialization of OncoGuide™ OncoScreen™ Plus CDx System in Japan. The CDx system received Manufacturing and Marketing Approval from Japan's MHLW as companion diagnostic for AstraZeneca's capivasertib (Truqap) in breast cancer. Riken Genesis handles distribution, insurance coverage, and market access in Japan.
  • Dizal PharmaceuticalcoreStrategic or Co-development Partner · 11 October 2024Joint development and co-commercialization of companion diagnostics for EGFR exon20ins mutation detection supporting sunvozertinib targeted therapy for NSCLC. This represents the first co-developed NGS-based CDx for lung cancer approved by NMPA following CDx guideline release in China.
  • BayermajorStrategic or Co-development Partner · 21 August 2024Collaboration to increase patient access to precision cancer medicines through companion diagnostics development and commercialization.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 25 October 2023Master Service Agreement for oncology companion diagnostics development, focusing on clinical trials for MDM2-p53 antagonist brigimadlin (BI 907828) and CDx product development in China. The partnership aims to provide precise treatment options for patients with MDM2-amplified, TP53 wild-type cancers including biliary tract carcinoma.
  • Merck KGaA (Germany)majorStrategic or Co-development Partner · 17 November 2021Collaboration on liquid biopsy-based CDx development using Burning Rock's OncoCompass Target platform, supporting Merck's oncology drug development programs.
  • IMPACT TherapeuticscoreStrategic or Co-development Partner · 3 August 2021Global strategic partnership for companion diagnostics development for Senaparib (PARP inhibitor) targeting prostate cancer. Includes CDx submissions to both FDA and NMPA, supported by Burning Rock's CLIA and CAP accredited labs.
  • National Cancer Center / Cancer Hospital of Chinese Academy of Medical SciencesmajorStrategic or Co-development Partner · 19 May 2021Launch of PRESCIENT study, the first blood-based, pan-cancer early-detection study in China using multi-omics approach. Expected to enroll 11,879 participants across 22 cancer types. Led by Professor Jie He and Professor Jie Wang from National Cancer Center.
  • Abbisko TherapeuticsmajorStrategic or Co-development Partner · 29 April 2021Strategic partnership for CDx assay development for ABSK091 (FGFR inhibitor) to detect FGFR genetic alterations in patients with urothelial carcinoma. Abbisko has exclusive global rights for development, manufacture, and commercialization.
  • CStone PharmaceuticalsmajorStrategic or Co-development Partner · 29 June 2020Strategic partnership for co-development and commercialization of companion diagnostics for pralsetinib (Blueprint Medicines) for detection of RET alterations in cancer patients in China.
  • IlluminacoreTechnology or Integration · 11 May 2020Strategic cooperation to promote development and standardization of NGS-based cancer therapy selection in China based on NextSeq 550Dx system. First genetic testing company in China to achieve development of IVD tests for both ctDNA and tissue based on NextSeq 550Dx system.
  • Shanghai Zhongshan HospitalmajorStrategic or Co-development Partner · 7 May 2020Collaboration on PREDICT (Pan-CanceR Early DetectIon ProjecT) study, the first early detection study in multiple cancer types in China. 14,000 patient enrollment expected. Led by Professor Jia Fan, Fellow of Chinese Academy of Sciences and President of Shanghai Zhongshan Hospital.
  • CTONG (Chinese Thoracic Oncology Group)majorStrategic or Co-development Partner · 1 August 2016Co-founded NGS Clinical Research Lab at Guangzhou International Bio Island for non-profit clinical studies. 3,000m2 facility with 19 independent labs covering sample processing, nucleic acid extraction, library construction, sequencing, and data analysis. CTONG's first partner for founding NGS lab.
  • AstraZeneca ChinamajorStrategic or Co-development Partner · 1 January 2016Designated as AstraZeneca's sole strategic NGS lung cancer testing partner. Participated in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD). Also launched China's first NGS charitable project for ovarian cancer - 'Love Me, Test Me' BRCA testing project.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Burning Rock Biotech competitors and assessment

Company assessment

Broad incumbents

  • NeoGenomics: US-listed oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE, RaDaR MRD). Comparable in oncology-focused lab services, NGS profiling, and pharma/biopharma clinical trial support.
  • Foundation Medicine (Roche): Roche-owned leader in NGS-based comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head with Burning Rock's OncoScreen Plus and OncoCompass products in CDx and tissue profiling, with broader pharma services scale.
  • Exact Sciences: US-listed molecular diagnostics company with Cologuard (CRC screening), Oncotype DX, and emerging liquid biopsy products. Comparable in cancer molecular diagnostics for therapy selection and screening, though broader and larger-scale than Burning Rock.

Direct peers

  • Caris Life Sciences: US-based molecular profiling company offering MI Profile tumor/NGS profiling and Caris Assure liquid biopsy MRD tests. Directly comparable to Burning Rock's tissue and blood-based NGS oncology products targeting therapy selection and recurrence monitoring.
  • Natera: US-listed molecular diagnostics company with Signatera tumor-informed MRD test and oncology NGS products. Direct comparable in liquid biopsy MRD detection (vs. Burning Rock's CanCatch) and oncology therapy selection testing.
  • Guardant Health: US-listed liquid biopsy and NGS oncology diagnostics company offering ctDNA-based therapy selection and MRD tests (Guardant360, Reveal). Directly comparable to Burning Rock's OncoCompass liquid biopsy franchise in product category, customer base (oncologists/hospitals), and business model.
  • Personalis: US-listed NGS-based oncology testing company offering NeXT Personal MRD test and ImmunoID Next tumor profiling. Comparable in tumor-informed liquid biopsy MRD and comprehensive NGS oncology panels for pharma and clinical customers.
  • Tempus AI: US-listed precision medicine company offering NGS-based oncology profiling (Tempus xT, xR), AI-enabled clinical decision support, and biopharma data services. Comparable in NGS oncology testing, pharma CDx/biomarker services, and AI/bioinformatics platform offerings.
  • Geneseeq Technology: China-based NGS oncology diagnostics competitor offering Gene+Seq tumor profiling, liquid biopsy, and pharma CDx services. Closest China-domestic direct peer to Burning Rock in NGS oncology testing market, technology, and pharma partnership model.

Emerging players

  • Predicine: US/China-based liquid biopsy and NGS diagnostics company offering cell-free DNA/RNA assays and MRD detection for pharma and clinical customers. Comparable in liquid biopsy ctDNA technology, MRD focus, and dual US-China operational footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Burning Rock Biotech social profiles

Digital presence

Burning Rock Biotech compliance and trust

Trust signal

Compliance11 records

Burning Rock Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Burning Rock Biotech leadership team

Management profile

Number of profiles

Profiles3 records

Burning Rock Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Burning Rock Biotech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Burning Rock Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Burning Rock Biotech

What does Burning Rock Biotech do?

Burning Rock Biotech develops and sells NGS-based diagnostic kits (tissue and liquid biopsy panels) and provides central laboratory cancer genomic testing services, multi-cancer early detection blood tests, and MRD monitoring products. It also delivers companion diagnostics development and biomarker services to pharmaceutical companies, supported by CLIA/CAP-accredited labs in China and the US.

Is Burning Rock Biotech a public or private company?

Burning Rock Biotech is a public company. It is classified as public and is currently operating.

When was Burning Rock Biotech founded?

Burning Rock Biotech was founded in 2015. It employs 101 to 250 people.

Where is Burning Rock Biotech based?

Burning Rock Biotech is headquartered in Guangzhou, China, in the Asia region.

How does Burning Rock Biotech make money?

Three revenue lines are on record. Central Laboratory Testing Services are the primary driver. The others are in-Hospital Testing Business and pharma Research and Development Services.

Who are Burning Rock Biotech's main competitors?

Broad incumbents on record are NeoGenomics, Foundation Medicine (Roche) and Exact Sciences. Direct peers are Caris Life Sciences, Natera, Guardant Health, Personalis, Tempus AI and Geneseeq Technology. Predicine is listed as an emerging player.

Does Burning Rock Biotech have an API?

No public API is recorded for Burning Rock Biotech.

What industry is Burning Rock Biotech in?

Burning Rock Biotech's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingBurning Rock's STELLA Shows 65.9% Sensitivity, 97.2% Specificity in Breast Lesion StudyBurning Rock Biotech presented STELLA breast lesion validation results at ESMO Congress on October 27, 2026. The 516-patient PERCEIVE-BREAST study showed STELLA's sensitivity of 65.9% and specificity of 97.2%, with detection improving by disease stage. Negative results alone cannot rule out malignancy, requiring follow-up imaging and pathological examination.Markets DailyXTL Biopharmaceuticals (NASDAQ:XTLB) & Burning Rock Biotech (NASDAQ:BNR) Critical ComparisonA comparison of XTL Biopharmaceuticals and Burning Rock Biotech evaluates profitability, valuation, and institutional ownership. Burning Rock Biotech has higher revenue ($77.16M vs $450K) and lower P/E, while XTL beats on 7 of 10 factors. Burning Rock trades at a lower price-to-earnings ratio.Markets DailyCentury Therapeutics (NASDAQ:IPSC) vs. Burning Rock Biotech (NASDAQ:BNR) Head to Head ContrastCentury Therapeutics and Burning Rock Biotech are compared on valuation, ratings, and ownership. Century Therapeutics has a stronger consensus rating, higher institutional ownership, and a 223% upside target, beating Burning Rock on 9 of 14 factors.American Banking and Market NewsHead-To-Head Comparison: Burning Rock Biotech (NASDAQ:BNR) vs. XTL Biopharmaceuticals (NASDAQ:XTLB)A head-to-head comparison of XTL Biopharmaceuticals and Burning Rock Biotech evaluates their financials, ownership, and analyst ratings. Burning Rock Biotech has higher revenue ($77.16M vs $450K) and lower valuation, while XTL Biopharmaceuticals beats on 8 of 11 factors. Both companies are small-cap healthcare firms with different therapeutic focuses.AInvestBNR Flat After Hours Amid Regulatory Progress for Cancer Testing KitsBurning Rock Genomics traded flat in after-hours sessions, reporting Q2 revenue of 134.7 million yuan. Its OncoScreen BCMatch kit entered priority review, CanCatch entered special review, and the OncoCompass liquid biopsy kit's priority review application was accepted in August.AInvestBurning Rock (BNR) rises 13.31% intraday after clinical study presentations at WCLC 2026Burning Rock shares rose 13.31% intraday after the company and its clinical collaborators presented three clinical studies at the 2026 World Conference on Lung Cancer. The presentations, using OncoScreen and OncoCompass platforms, covered LUAD biology, LUSC treatment response prediction, and pleural effusion testing, validating the clinical utility of its technologies.Markets DailyBurning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results, Beats Estimates By $2.09 EPSBurning Rock Biotech reported Q4 EPS of -$0.20, beating estimates by $2.09, with revenue of $19.84 million. The stock rose 5.7% to $12.28, while analysts' consensus remains a Sell rating. Insider Yusheng Han bought 24,900 shares at $8.00.Ticker ReportBurning Rock Biotech (BNR) Projected to Announce Quarterly Earnings on WednesdayBurning Rock Biotech is expected to announce Q2 2026 earnings on September 2nd, with analysts projecting a loss of $2.29 per share and revenue of $19.21 million. The company's consensus rating is Sell, and its stock opened at $9.45 on Tuesday.GurufocusIs Burning Rock Biotech Ltd (BNR) Overvalued After 6.5% Rally? GGuruFocus reported on August 26, 2026 that Burning Rock Biotech Ltd shares rose 6.5% to $10.44, trading within a 52-week range of $6.79 to $41.72. The firm's GF Value estimate of $7.45 implies 40.1% overvaluation, while a GF Score of 57/100 reflects average financial health and weak profitability. Insiders bought $11.6M in shares over the past year.Ticker ReportSinovac Biotech (NASDAQ:SVA) versus Burning Rock Biotech (NASDAQ:BNR) Head to Head AnalysisThis article presents a comparative financial analysis of two small-cap healthcare companies, Burning Rock Biotech and Sinovac Biotech, evaluating metrics such as volatility, profitability, analyst ratings, ownership, and valuation. The data indicates that while Sinovac Biotech generates significantly higher revenue, both companies reported net losses, with Burning Rock showing slightly better earnings performance despite lower top-line sales. Analyst sentiment appears negative for Burning Rock due to sell ratings, whereas Sinovac lacked sufficient rating data in the provided snippet.